(Isstories Editorial):- Stamford, US Aug 22, 2025 (Issuewire.com) – Harrison Global Holdings Inc., formerly BloomZ Inc., has signed a strategic international partnership with Biotree Co., Ltd., a Korean biotech pioneer developing the world’s first natural product-based drug for metabolic syndrome.
Why This Matters to Investors
- Biotree’s PH-100 has completed Phase 1 trials in the U.S. and Phase 2A trials in Korea, showing strong results in reducing inflammation and improving cardiovascular health.
- The drug is expected to receive conditional approval by mid-2026, opening up prescription-only revenue streams.
- Biotree is the first Korean firm to extract Seapolynol from Gamtae seaweed–used in health foods, cosmetics, and pharmaceuticals.
- Harrison Global will help expand Biotree’s reach into the U.S., Japan, China, and broader Asia through joint ventures, licensing, and localized development.
Strategic Synergy
More on Isstories:
- FirstQFM AB secures €1.2 million to accelerate commercial quantum computing with proprietary foundation models
- Bhurr Captivating Audiences With His Brilliant Electronic Dance Music Numbers
- FurGPT (FGPT) Secures $80M Investment from KaJ Labs to Accelerate Token Rollout
- Atua AI Strengthens Execution Tuning Systems for Dependable Network Operations
- ProSpec – High-Quality Recombinant Proteins for Research
This partnership blends Harrison’s entertainment and youth engagement expertise with Biotree’s biotech innovation, creating a hybrid growth engine across lifestyle, wellness, and media sectors.
Executive Insight
“We’re thrilled to contribute to global health by supporting Biotree’s breakthrough treatment,” said Ryoshin Nakade, Co-CEO of Harrison Global. “This partnership reflects our commitment to innovation and international expansion.”
Enrique Vargas
(845) 288-0020
Vargas Financial Inc
